Link between sphingolipids and complement signaling may be key to stopping cancer metastasis

by Caroline Wallace,Medical University of South CarolinaGraphical Abstract. Credit:Cell Reports(2022). DOI: 10.1016/j.celrep.2022.111742MUSC Hollings Cancer Center researchers have i

Updated on: January 02,2024

Link between sphingolipids and complement signaling may be key to stopping cancer metastasis

by Caroline Wallace,Medical University of South CarolinaGraphical Abstract. Credit:Cell Reports(2022). DOI: 10.1016/j.celrep.2022.111742MUSC Hollings Cancer Center researchers have i

Updated on:January 02,2024

Drug makes tumors more susceptible to chemo

by Massachusetts Institute of TechnologyStructure of the complex containing Rev1 and JH-RE-06. The two copies of the Rev1 protein are shown in dark and light blue, while the small molecule JH-RE-

Updated on: May 25,2024

Drug makes tumors more susceptible to chemo

by Massachusetts Institute of TechnologyStructure of the complex containing Rev1 and JH-RE-06. The two copies of the Rev1 protein are shown in dark and light blue, while the small molecule JH-RE-

Updated on:May 25,2024

Study: AI outperforms standard risk model for predicting breast cancer

by Radiological Society of North AmericaRight medial lateral oblique (RMLO) screening mammograms show negative results from 2016 in (A) a 73-year-old woman with Mirai artificial intelligence (AI)

Updated on: February 03,2024

Study: AI outperforms standard risk model for predicting breast cancer

by Radiological Society of North AmericaRight medial lateral oblique (RMLO) screening mammograms show negative results from 2016 in (A) a 73-year-old woman with Mirai artificial intelligence (AI)

Updated on:February 03,2024

New treatment trialed in mice offers hope for advanced liver cancer

by Centenary InstituteCD5-2 treatment improved tumor vessels structure. Representative scanning electron microscopy images of liver tumor blood vessels in the different treatment groups. Qualitat

Updated on: February 18,2024

New treatment trialed in mice offers hope for advanced liver cancer

by Centenary InstituteCD5-2 treatment improved tumor vessels structure. Representative scanning electron microscopy images of liver tumor blood vessels in the different treatment groups. Qualitat

Updated on:February 18,2024

Multi-modal AI models for intermediate- to high-risk localized prostate cancer

by NRG OncologyCredit: Pixabay/CC0 Public DomainNRG Oncology investigators analyzed clinical and digital histopathology data from five Phase III prostate cancer trials (NRG/RTOG 9202, 9408, 9413, 9910

Updated on: January 30,2024

Multi-modal AI models for intermediate- to high-risk localized prostate cancer

by NRG OncologyCredit: Pixabay/CC0 Public DomainNRG Oncology investigators analyzed clinical and digital histopathology data from five Phase III prostate cancer trials (NRG/RTOG 9202, 9408, 9413, 9910

Updated on:January 30,2024

Researchers identify new gene mutation in familial thyroid cancers

by Pennsylvania State UniversityCredit: CC0 Public DomainResearchers from Penn State College of Medicine identified a new gene mutation that may cause a type of familial thyroid cancer. Dr. Darri

Updated on: June 04,2024

Researchers identify new gene mutation in familial thyroid cancers

by Pennsylvania State UniversityCredit: CC0 Public DomainResearchers from Penn State College of Medicine identified a new gene mutation that may cause a type of familial thyroid cancer. Dr. Darri

Updated on:June 04,2024

Discovering cancers of epigenetic origin without DNA mutation

byCNRSExample of a tumor obtained by reducing the expression levels of a Polycomb protein. On the left is an example of precursor tissue of the eye during normal development. On the right, a tum

Updated on: April 28,2024

Discovering cancers of epigenetic origin without DNA mutation

byCNRSExample of a tumor obtained by reducing the expression levels of a Polycomb protein. On the left is an example of precursor tissue of the eye during normal development. On the right, a tum

Updated on:April 28,2024

Adcetris FDA approval expanded to include later-stage Hodgkin's

(HealthDay)—U.S. Food and Drug Administration approval of Adcetris (brentuximab vedotin) has been expanded to include adults with untreated stage III or IV classical Hodgkin's lymphoma, the agency

Updated on: March 30,2024

Adcetris FDA approval expanded to include later-stage Hodgkin's

(HealthDay)—U.S. Food and Drug Administration approval of Adcetris (brentuximab vedotin) has been expanded to include adults with untreated stage III or IV classical Hodgkin's lymphoma, the agency

Updated on:March 30,2024

Active surveillance OK for non-muscle invasive bladder cancer

(HealthDay)—For patients with non-muscle invasive bladder cancer, active surveillance seems reasonable and cost-effective, according to a study published in the February issue ofThe Journal of U

Updated on: April 07,2024

Active surveillance OK for non-muscle invasive bladder cancer

(HealthDay)—For patients with non-muscle invasive bladder cancer, active surveillance seems reasonable and cost-effective, according to a study published in the February issue ofThe Journal of U

Updated on:April 07,2024

ASCO: Low-fat dietary pattern cuts breast cancer deaths

(HealthDay)—A low-fat dietary intervention is associated with reductions in deaths after breast cancer and deaths from breast cancer among postmenopausal women after long-term follow-up, according to

Updated on: March 30,2024

ASCO: Low-fat dietary pattern cuts breast cancer deaths

(HealthDay)—A low-fat dietary intervention is associated with reductions in deaths after breast cancer and deaths from breast cancer among postmenopausal women after long-term follow-up, according to

Updated on:March 30,2024

New hormonal agent may slow progression of early-stage prostate cancer during active surveillance

byWolters Kluwer HealthPositive biopsy-free survival with 95% confidence limits (shaded gray areas). Credit:Journal of Urology(2023). DOI: 10.1097/JU.0000000000003038For men with ear

Updated on: January 12,2024

New hormonal agent may slow progression of early-stage prostate cancer during active surveillance

byWolters Kluwer HealthPositive biopsy-free survival with 95% confidence limits (shaded gray areas). Credit:Journal of Urology(2023). DOI: 10.1097/JU.0000000000003038For men with ear

Updated on:January 12,2024

Genome offers clues to esophageal cancer disparity

by University of MichiganEsophagus graphic. Credit: Michigan MedicineA change in the genome of Caucasians could explain much-higher rates of the most common type of esophageal cancer in this popu

Updated on: March 06,2024

Genome offers clues to esophageal cancer disparity

by University of MichiganEsophagus graphic. Credit: Michigan MedicineA change in the genome of Caucasians could explain much-higher rates of the most common type of esophageal cancer in this popu

Updated on:March 06,2024